Older IBD patients with comorbidities are less likely to be hospitalized due to an infection if they are treated with vedolizumab or ustekinumab than with an anti-TNF agent, suggests a US study.
Vedolizumab Is Safer in Older Adults With IBD medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
This article is a collaboration between MedPage Today and:
Among older adults with inflammatory bowel disease (IBD), vedolizumab (Entyvio) appeared to be safer than tumor necrosis factor (TNF) inhibitors, a large retrospective study suggested.
After weighting using standardized mean differences, new users of vedolizumab had a lower likelihood of all-cause hospitalization during the 12 months after initiating biologic treatment compared with those starting TNF inhibitors, with a hazard ratio of 0.81 (95% CI 0.68-0.96), according to Bharati Kochar, MD, of Massachusetts General Hospital in Boston.
In addition, while there was no difference between vedolizumab and anti-TNF initiators in IBD-related hospitalizations, those on vedolizumab had a lower risk of infection-related hospitalization, with a hazard ratio of 0.39 (95% CI 0.23-0.65), she reported at the virtual Crohn s and Colitis Congress.